Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis

Authors

  • Raquel Montáns-García Primary Care Service of Cee, Health Area of ​​A Coruña and Cee, SERGAS, Cee, A Coruña, Spain https://orcid.org/0000-0003-0887-1284
  • María Sevilla-Ortiz Rational Use of Medicines and Pharmaceutical Care Service, SERGAS, Ministry of Health, Santiago de Compostela, La Coruña, Spain https://orcid.org/0009-0004-9337-1923
  • Ana Pequeño-Prieto Primary Care Service of Cee, Health Area of ​​A Coruña and Cee, SERGAS, Cee, A Coruña, Spain https://orcid.org/0009-0006-6582-7895

DOI:

https://doi.org/10.32818/reccmi.a11n1a4

Keywords:

Pneumocystis jirovecii, Pneumocystis jirovecii prophylaxis, trimethoprim sulfamethoxazole drug combination, rheumatic disease, methotrexat

Abstract

Pneumocystis jirovecii (PJ) pneumonia is an opportunistic infection with a low incidence in patients with autoimmune
and/or inflammatory diseases, but it is associated with significant morbidity and mortality. Primary prophylaxis
is not routinely recommended, so it is important to identify factors that predispose to a higher risk of
developing this infection in order to ensure the earliest possible diagnosis and treatment.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Raquel Montáns-García, Primary Care Service of Cee, Health Area of ​​A Coruña and Cee, SERGAS, Cee, A Coruña, Spain

Primary Care Pharmacist at SAP de Cee, Sergas, A Coruña, Spain.

Ana Pequeño-Prieto, Primary Care Service of Cee, Health Area of ​​A Coruña and Cee, SERGAS, Cee, A Coruña, Spain

Primary care physician at the Health Center of Cee, A Coruña, Spain

References

Vela Casasempere P, Ruíz Torregosa P, García Sevila R. Pneumocystis jirovecii en pacientes inmunocomprometidos con enfermedades reumáticas. Reumatol Clin. (Engl Ed). 2021; 17(5): 290-296. doi: http://dx.doi.org/10.1016/j.reuma.2020.02.006 (último acceso abr. 2026). DOI: https://doi.org/10.1016/j.reuma.2020.02.006

Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D. Risk factors and prevention of Pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases. Chest. 2020; 158(6): 2323-2332. doi: http://dx.doi.org/10.1016/j.chest.2020.05.558 (último acceso abr. 2026). DOI: https://doi.org/10.1016/j.chest.2020.05.558

Mori S, Sugimoto M. Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: Risks and prophylaxis recommendations. Clin Med Insights Circ Respir Pulm Med. 2015; 9(Suppl 1): 29-40. doi: http://dx.doi.org/10.4137/CCRPM.S23286 (último acceso abr. 2026). DOI: https://doi.org/10.4137/CCRPM.S23286

Guía de práctica clínica para el manejo de pacientes con artritis reumatoide. Sociedad Española de Reumatología. Edición: 2019. Accesible en: https://www.ser.es/wp-content/uploads/2019/03/Guia-de-Practica-Clinica-para-el-Manejo-de-Pacientes-con-Artritis-Reumatoide.pdf (último acceso abr. 2026).

Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023; 82(6): 742-753. doi: http://dx.doi.org/10.1136/ard-2022-223335F (último acceso abr. 2026).

Hall JJ, Bolina M, Chatterley T, Jamali F. Interaction between low-dose methotrexate and nonsteroidal anti-inflammatory drugs, penicillins, and proton pump inhibitors: a narrative review of the literature. Ann Pharmacother. 2017; 51(2): 163-178. doi: http://dx.doi.org/10.1177/1060028016672035 (último acceso abr. 2026). DOI: https://doi.org/10.1177/1060028016672035

Lagrou K, Chen S, Masur H, Viscoli C, Decker CF, Pagano L, et al. Pneumocystis jirovecii disease: basis for the revised EORTC/MSGERC invasive fungal disease definitions in individuals without human immunodeficiency virus. Clin Infect Dis. 2021; 72(Suppl 2): 114-120. doi: https://doi.org/10.1093/cid/ciaa1805 (último acceso abr. 2026). DOI: https://doi.org/10.1093/cid/ciaa1805

Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World. 2002; 24(2): 46-54. doi: https://doi.org/10.1023/a:1015570104121 (último acceso abr. 2026). DOI: https://doi.org/10.1023/A:1015570104121

Downloads

Published

2026-04-23

How to Cite

1.
Montáns-García R, Sevilla-Ortiz M, Pequeño-Prieto A. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis. Rev Esp Casos Clin Med Intern [Internet]. 2026 Apr. 23 [cited 2026 May 1];11(1):10-2. Available from: https://www.reccmi.com/RECCMI/article/view/1243

Issue

Vol. 11 No. 1 (2026): Revista Española de Casos Clínicos en Medicina Interna

Section

CLINICAL CASES

License

Copyright (c) 2026 Raquel Montáns-García, María Sevilla-Ortiz, Ana Pequeño-Prieto

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:

Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.

No comercial: no puede utilizar el material con fines comerciales.

No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.

Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.

Crossref
Scopus
Google Scholar
Europe PMC